Investors & Media

News

ALL RELEASES

Summary Toggle Cyclacel Reviews 2017 Achievements and Announces Key Business Objectives for 2018

01/09/18

Company to Present at the Biotech ShowcaseTM 2018 Conference
Read more
Summary Toggle Cyclacel Announces Presentation of Results From Phase 3 Seamless Study at Ash Annual Meeting

12/12/17

BERKELEY HEIGHTS, N.J., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) "Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target various phases of cell cycle control for the treatment of cancer and other serious
Read more

Cyclacel Announces Presentation of Results From Phase 3 Seamless Study at Ash Annual Meeting 24.7 KB
Summary Toggle Cyclacel Pharmaceuticals Reports Third Quarter 2017 Financial Results

11/09/17

— Conference Call Scheduled November 9, 2017 at 4:30 p.m. ET —
Read more

Cyclacel Pharmaceuticals Reports Third Quarter 2017 Financial Results 46.1 KB
Summary Toggle Cyclacel Pharmaceuticals to Release Third Quarter 2017 Financial Results

11/02/17

BERKELEY HEIGHTS, N.J., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted
Read more

Cyclacel Pharmaceuticals to Release Third Quarter 2017 Financial Results 18 KB
Summary Toggle Cyclacel Pharmaceuticals Announces That Full Results From the Phase 3 Seamless Trial Have Been Selected for Oral Presentation at ASH 2017 Annual Meeting

11/01/17

BERKELEY HEIGHTS, N.J., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted
Read more

Cyclacel Pharmaceuticals Announces That Full Results From the Phase 3 Seamless Trial Have Been Selected for Oral Presentation at ASH 2017 Annual Meeting 19.6 KB
Summary Toggle Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference

09/21/17

BERKELEY HEIGHTS, N.J., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted
Read more

Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference 17.9 KB
Summary Toggle Cyclacel Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

09/08/17

BERKELEY HEIGHTS, N.J., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted
Read more

Cyclacel Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference 17.3 KB
Summary Toggle Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results

08/09/17

Conference Call Scheduled August 9, 2017 at 4:30 p.m. EDT

Read more

Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results 43 KB
Summary Toggle Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression

08/07/17

Part 2 of study will focus on cyclin E amplified drug resistant solid tumors

Read more

Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression 26.5 KB
Summary Toggle Cyclacel Pharmaceuticals to Release Second Quarter 2017 Financial Results

08/02/17

BERKELEY HEIGHTS, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other
Read more

Cyclacel Pharmaceuticals to Release Second Quarter 2017 Financial Results 17.7 KB
Summary Toggle Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

07/21/17

BERKELEY HEIGHTS, N.J., July 21, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for
Read more

Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option 20.5 KB
Summary Toggle Cyclacel Announces Pricing of $13.2 Million Underwritten Public Offering

07/19/17

BERKELEY HEIGHTS, N.J., July 19, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for
Read more

Cyclacel Announces Pricing of $13.2 Million Underwritten Public Offering 20.2 KB
Summary Toggle Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results

05/11/17

Conference Call Scheduled May 11, 2017 at 4:30 p.m. EDT

Read more

Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results 38.6 KB
Summary Toggle Cyclacel Pharmaceuticals to Release First Quarter 2017 Financial Results

05/05/17

BERKELEY HEIGHTS, N.J., May 05, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other
Read more

Cyclacel Pharmaceuticals to Release First Quarter 2017 Financial Results 17.2 KB
Summary Toggle Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140

04/04/17

- Preclinical Data Presented at the AACR 2017 Meeting - BERKELEY HEIGHTS, N.J., April 04, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), today announced the presentation of preclinical data outlining the potential therapeutic utility
Read more

Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140 22.5 KB
Summary Toggle Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways

04/02/17

- Preclinical Data Presented at the AACR 2017 Meeting -

Read more

Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways 23.6 KB
Summary Toggle Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results

03/28/17

Conference Call Scheduled March 28, 2017 at 4:30 p.m. EDT

Read more

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results 41.3 KB
Summary Toggle Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2016 Financial Results

03/21/17

BERKELEY HEIGHTS, N.J., March 21, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other
Read more

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2016 Financial Results 17.2 KB
Summary Toggle Cyclacel's CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI

03/07/17

CYC065 found effective against lung cancer cell lines including those with KRAS mutations

Read more

Cyclacel's CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI 21 KB
Summary Toggle Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia

02/23/17

- Study did not reach statistically significant improvement in the primary endpoint of overall survival - - Improvement in secondary endpoint of complete remission rate for the experimental arm - - Conference call scheduled today at 9:00 AM Eastern Time - BERKELEY HEIGHTS, N.J., Feb.
Read more

Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia 26.9 KB

Share this on:
Delicious
Digg
Facebook
LinkedIn
Twitter